This has been a hard year for Lexicon Pharmaceuticals (LXRX),
and I can understand why any good news would be welcome. Unfortunately,
the three positive trial read-outs the company has offered in December
don’t really change the value proposition and don’t really represent any
positive change in the outlook.
As is, Lexicon
still needs to find a partner for its lead drug sotagliflozin and figure
out how to manage its cash needs. More significant data from the
TELE-ABC study in 2020 could certainly help, and maybe the company will
be able to produce proof-of-concept data on its chronic/neuropathic pain
drug LX9211, but for now a partner for sotagliflozin is far and away at
the top Lexicon’s Christmas list.
Read the full article here:
Lexicon Needs More Than Incremental Positive Clinical Data
No comments:
Post a Comment